Thesis
How the mighty have fallen applies directly to Gilead (NASDAQ:GILD) and Bristol-Myers Squibb (NYSE:BMY). Gilead is in the midst of a two year downtrend while Bristol is on the low end of some volatile price swings. There is a case for and against each company. It is up to you to decide if the rewards outweigh the risk. In my opinion, both appear to be good long term investments.
The Backstory Of Gilead
Gilead's rise to fame was a result of its Hep C drug. Surprisingly, or not, the decline of its Hep C drug is also the reason for its demise. The company is running out of people to sell to as it faces increased pressure from competitors. So is Gilead a one trick pony? I don't think so. But first, shown in Figure 1 is the five year chart for Gilead. Or, the rise and fall of Gilead as it would appear. As you can see, Gilead is at a multi-year low and nearly 50% off its all time high.
